The ẞ-site APP cleaving enzyme-1 (BACE1) is involved in the rate-limiting step of the cleavage process of the amyloid precursor protein (APP), leading to the generation of the neurotoxic amyloid β (Aβ) protein, which is the next attractive target for the treatment of AD [5]. Here, APP is linked to Alzheimer disease.